ART-001 / Artec Biotech - LARVOL DELTA

New Findings on Natural Killer (NK) Cells as Cancer Therapy for Glioblastoma, Leukemia and Lymphoma Published by Rosalind Franklin University Incubator Company (PRNewswire) - "Artec Biotech...is developing a potentially promising treatment for glioblastoma multiforme (GBM), a deadly cancer for which patients have few if any therapeutic alternatives. Artec is a developer of technology to convert stem cells to natural killer (NK) cells, which are less toxic and more efficient than other platforms for cellular immunotherapy....'Our research assessed the authenticity, efficacy and toxicity of hPSCs-NK in vitro and in vivo, revealing advantages over peripheral blood-derived NK cells that include diminished checkpoint inhibition signaling and enhanced metabolic gene expression'....'It also showed significant efficacy against cancers like leukemias and lymphoma, in addition to GBM'."

Preclinical • Glioblastoma • Leukemia • Lymphoma